Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients

被引：0
|
作者：
Numan, L. [1 ]
Aarts, E. [2 ]
Ramjankhan, F. [3 ]
Van der Meer, M. G. [1 ]
Oerlemans, M. [4 ]
De Jonge, N. [1 ]
Oppelaar, A. [3 ]
Kemperman, H. [5 ]
Asselbergs, F. [4 ]
Van Laake, L. W. [1 ]
机构：
[1] Univ Med Ctr Utrecht, Cardiol, Utrecht, Netherlands
[2] Univ Utrecht, Methodol Stat, Utrecht, Netherlands
[3] Univ Med Ctr Utrecht, Cardiothorac Surg, Utrecht, Netherlands
[4] Univ Med Ctr Utrecht, Cardiol, Utrecht, Netherlands
[5] Univ Med Ctr Utrecht, Cent Diagnost Lab, Utrecht, Netherlands
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2023年 / 42卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
834
引用
收藏
页码：S364 / S365
页数：2
相关论文
共 50 条
  • [1] Soluble Suppression of Tumorigenicity-2 Predicts Mortality and Right Heart Failure in Patients With a Left Ventricular Assist Device
    Numan, Lieke
    Aarts, Emmeke
    Ramjankhan, Faiz
    Oerlemans, Marish I. F.
    van der Meer, Manon G.
    de Jonge, Nicolaas
    Oppelaar, Anne-Marie
    Kemperman, Hans
    Asselbergs, Folkert W.
    Van Laake, Linda W.
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (02):
  • [2] The Continuation of Trickle-Down Medicine: Soluble Suppression of Tumorigenicity-2 (sST2) in Pediatric Heart Failure
    Greenway, Steven C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (06) : 692 - 693
  • [3] Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study
    Zhu Min
    Liu Xuelu
    Zhang Ran
    Shu Qiuhong
    Meng Yong
    ADVANCES IN THERAPY, 2022, 39 (12) : 5514 - 5529
  • [4] Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study
    Zhu Min
    Liu Xuelu
    Zhang Ran
    Shu Qiuhong
    Meng Yong
    Advances in Therapy, 2022, 39 : 5514 - 5529
  • [5] Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure-A Prospective Observational Study
    Dworok, Victoria
    Haehnel, Valentin
    Bannehr, Marwin
    Paar, Vera
    Edlinger, Christoph
    Lichtenauer, Michael
    Butter, Christian
    Haase-Fielitz, Anja
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [6] Differential and Predictive Value of Galectin-3 and Soluble Suppression of Tumorigenicity-2 (sST2) in Heart Failure with Preserved Ejection Fraction
    Cui, Yameng
    Qi, Xin
    Huang, Anan
    Li, Jiao
    Hou, Wenguang
    Liu, Keqiang
    MEDICAL SCIENCE MONITOR, 2018, 24 : 5139 - 5146
  • [7] Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
    Huang, Dong-Hui
    Sun, Hao
    Shi, Jing-Pu
    CHINESE MEDICAL JOURNAL, 2016, 129 (05) : 570 - 577
  • [8] Diagnostic Value of Soluble Suppression of Tumorigenicity-2 for Heart Failure
    Huang Dong-Hui
    Sun Hao
    Shi Jing-Pu
    中华医学杂志英文版, 2016, 129 (05) : 570 - 577
  • [9] Prognostic role of soluble suppression of tumorigenicity-2 on cardiovascular mortality in outpatients with heart failure
    Gul, Ibrahim
    Yucel, Oguzhan
    Zararsiz, Abdullah
    Demirpence, Ozlem
    Yucel, Hasan
    Zorlu, Ali
    Yilmaz, Mehmet Birhan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2017, 18 (03): : 200 - 205
  • [10] Soluble suppression of tumorigenicity-2 for risk stratification in outpatients with heart failure
    Oncel, Can Ramazan
    ANATOLIAN JOURNAL OF CARDIOLOGY, 2018, 19 (03): : 228 - 228
12345